Bill Text: NY A08913 | 2013-2014 | General Assembly | Introduced


Bill Title: Establishes the sickle cell treatment act of 2014.

Spectrum: Partisan Bill (Democrat 16-0)

Status: (Introduced - Dead) 2014-02-28 - referred to health [A08913 Detail]

Download: New_York-2013-A08913-Introduced.html
                           S T A T E   O F   N E W   Y O R K
       ________________________________________________________________________
                                         8913
                                 I N  A S S E M B L Y
                                   February 28, 2014
                                      ___________
       Introduced  by  M. of A. SCARBOROUGH, CRESPO, SCHIMEL, HOOPER, JAFFEE --
         Multi-Sponsored by -- M. of A. DINOWITZ, PERRY, PRETLOW --  read  once
         and referred to the Committee on Health
       AN ACT to amend the social services law, in relation to establishing the
         sickle cell treatment act of 2014
         THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
       BLY, DO ENACT AS FOLLOWS:
    1    Section 1. This act shall be known and may be  cited  as  the  "sickle
    2  cell treatment act of 2014".
    3    S  2.  Legislative findings. The legislature hereby finds and declares
    4  the following:
    5    (1) Sickle cell disease (SCD) is an inherited  disease  of  red  blood
    6  cells that is a major health problem in the United States.
    7    (2)  Approximately  70,000  Americans have SCD and approximately 1,800
    8  American babies are born with the disease  each  year.  SCD  also  is  a
    9  global  problem  with  close  to  300,000  babies born annually with the
   10  disease.
   11    (3) In the United States, SCD is most common in African-Americans  and
   12  in  those of Hispanic, Mediterranean, and Middle Eastern ancestry. Among
   13  newborn American infants, SCD occurs in approximately 1 in 300  African-
   14  Americans, 1 in 36,000 Hispanics, and 1 in 80,000 Caucasians.
   15    (4)  More than 2,500,000 Americans, mostly African-Americans, have the
   16  sickle cell trait. These Americans are healthy carriers  of  the  sickle
   17  cell  gene who have inherited the normal hemoglobin gene from one parent
   18  and the sickle gene from the other parent. A sickle cell trait is not  a
   19  disease,  but when both parents have the sickle cell trait, there is a 1
   20  in 4 chance with each pregnancy that the child will be born with SCD.
   21    (5) Children with SCD may exhibit frequent pain  episodes,  entrapment
   22  of blood within the spleen, severe anemia, acute lung complications, and
   23  priapism.  During  episodes of severe pain, spleen enlargement, or acute
   24  lung complications, life threatening complications can develop  rapidly.
   25  Children  with  SCD  are  also  at  risk for septicemia, meningitis, and
   26  stroke. Children with SCD at highest risk for stroke can  be  identified
        EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                             [ ] is old law to be omitted.
                                                                  LBD02042-01-3
       A. 8913                             2
    1  and,  thus,  treated  early  with  regular blood transfusions for stroke
    2  prevention.
    3    (6)  The  most  feared  complication for children with SCD is a stroke
    4  (either overt or silent) occurring in 30 percent of  the  children  with
    5  sickle cell anemia prior to their 18th birthday and occurring in infants
    6  as  young  as 18 months of age. Students with SCD and silent strokes may
    7  not have any physical signs of such disease or strokes but  may  have  a
    8  lower  educational  attainment when compared to children with SCD and no
    9  strokes. Approximately 60 percent of students with silent  strokes  have
   10  difficulty in school, require special education, or both.
   11    (7)  Many  adults  with SCD have acute problems, such as frequent pain
   12  episodes and acute lung complications that can result in death.   Adults
   13  with SCD can also develop chronic problems, including pulmonary disease,
   14  pulmonary  hypertension,  degenerative  changes  in the shoulder and hip
   15  joints, poor vision, and kidney failure.
   16    (8) The average life span for an adult with SCD is the mid-40s.  While
   17  some patients can remain without symptoms for years, many others may not
   18  survive  infancy  or  early childhood. Causes of death include bacterial
   19  infection, stroke, and lung, kidney, heart, or liver failure.  Bacterial
   20  infections and lung injuries are leading causes of death in children and
   21  adults with SCD.
   22    (9)  As  a  complex  disorder  with  multisystem  manifestations,  SCD
   23  requires specialized comprehensive and continuous care  to  achieve  the
   24  best possible outcome. Newborn screening, genetic counseling, and educa-
   25  tion  of  patients and family members are critical preventative measures
   26  that decrease morbidity and mortality, delaying  or  preventing  compli-
   27  cations, in-patient hospital stays, and increased overall costs of care.
   28    (10)  Stroke  in  the  adult  SCD  population commonly results in both
   29  mental and physical disabilities for life.
   30    (11) Currently, one of the most effective  treatments  to  prevent  or
   31  treat  an  overt  stroke  or  a silent stroke for a child with SCD is at
   32  least monthly blood transfusions  throughout  childhood  for  many,  and
   33  throughout life for some, requiring removal of sickle blood and replace-
   34  ment with normal blood.
   35    (12)  With acute lung complications, transfusions are usually required
   36  and are often the only therapy demonstrated to prevent premature death.
   37    The legislature declares its intent to develop and establish  systemic
   38  mechanisms  to  improve  the  prevention  and  treatment  of sickle cell
   39  disease.
   40    S 3. Section 365 of the social services law is amended by  adding  two
   41  new subdivisions 13 and 14 to read as follows:
   42    13.  ANY  INCONSISTENT PROVISION OF THIS CHAPTER OR OTHER LAW NOTWITH-
   43  STANDING, THE DEPARTMENT SHALL BE  RESPONSIBLE  FOR  FURNISHING  MEDICAL
   44  ASSISTANCE  FOR  PREVENTATIVE MEDICAL STRATEGIES, INCLUDING PROPHYLAXIS,
   45  AND TREATMENT AND SERVICES FOR ELIGIBLE INDIVIDUALS WHO HAVE SICKLE CELL
   46  DISEASE. FOR THE PURPOSES OF  THIS  SUBDIVISION,  "PREVENTATIVE  MEDICAL
   47  STRATEGIES, TREATMENT AND SERVICES" SHALL INCLUDE, BUT NOT BE LIMITED TO
   48  THE FOLLOWING:
   49    (A) CHRONIC BLOOD TRANSFUSION (WITH DEFEROXAMINE CHELATION) TO PREVENT
   50  STROKE  IN INDIVIDUALS WITH SICKLE CELL DISEASE WHO HAVE BEEN IDENTIFIED
   51  AS BEING AT HIGH RISK FOR STROKE;
   52    (B) GENETIC COUNSELING AND TESTING FOR INDIVIDUALS  WITH  SICKLE  CELL
   53  DISEASE OR THE SICKLE CELL TRAIT; OR
   54    (C) OTHER TREATMENT AND SERVICES TO PREVENT INDIVIDUALS WHO HAVE SICK-
   55  LE CELL DISEASE AND WHO HAVE HAD A STROKE FROM HAVING ANOTHER STROKE.
       A. 8913                             3
    1    14.  ANY  INCONSISTENT PROVISION OF THIS CHAPTER OR OTHER LAW NOTWITH-
    2  STANDING, THE DEPARTMENT SHALL BE RESPONSIBLE FOR ARRANGING OR PROVIDING
    3  FUNDING FOR THE PREVENTION AND TREATMENT OF SICKLE CELL  DISEASE  DEMON-
    4  STRATION PROGRAM, AS DESCRIBED IN SECTION THREE HUNDRED SIXTY-THREE-F OF
    5  THIS TITLE.
    6    S  4. The social services law is amended by adding a new section 363-f
    7  to read as follows:
    8    S 363-F. PREVENTION AND TREATMENT OF SICKLE CELL DISEASE DEMONSTRATION
    9  PROGRAM. 1. THE COMMISSIONER OF HEALTH SHALL  ESTABLISH  AND  CONDUCT  A
   10  PREVENTION AND TREATMENT OF SICKLE CELL DISEASE DEMONSTRATION PROGRAM IN
   11  THE CITY OF NEW YORK AND FOR NO MORE THAN FIVE COUNTIES, FOR THE PURPOSE
   12  OF  DEVELOPING  AND  ESTABLISHING  SYSTEMIC  MECHANISMS  TO  IMPROVE THE
   13  PREVENTION AND TREATMENT OF SICKLE CELL DISEASE, INCLUDING THROUGH:
   14    (A) THE COORDINATION OF SERVICE DELIVERY FOR INDIVIDUALS  WITH  SICKLE
   15  CELL DISEASE;
   16    (B) GENETIC COUNSELING AND TESTING;
   17    (C) BUNDLING OF TECHNICAL SERVICES RELATED TO THE PREVENTION OF TREAT-
   18  MENT OF SICKLE CELL DISEASE;
   19    (D) TRAINING OF HEALTH PROFESSIONALS; AND
   20    (E)  IDENTIFYING  AND ESTABLISHING OTHER EFFORTS RELATED TO THE EXPAN-
   21  SION AND COORDINATION OF EDUCATION, TREATMENT, AND  CONTINUITY  OF  CARE
   22  PROGRAMS FOR INDIVIDUALS WITH SICKLE CELL DISEASE.
   23    2.  ON  OR  BEFORE  THE  FIRST  OF JANUARY, TWO THOUSAND EIGHTEEN, THE
   24  COMMISSIONER OF HEALTH SHALL REPORT TO THE GOVERNOR, THE SPEAKER OF  THE
   25  ASSEMBLY  AND  THE  TEMPORARY PRESIDENT OF THE SENATE ON THE IMPACT THAT
   26  THE PREVENTION  AND  TREATMENT  OF  SICKLE  CELL  DISEASE  DEMONSTRATION
   27  PROGRAM  HAS  HAD  ON INDIVIDUALS WITH SICKLE CELL DISEASE IN REGARDS TO
   28  COORDINATION OF SERVICE DELIVERY, GENETIC COUNSELING AND TESTING  BUNDL-
   29  ING  OF  TECHNICAL  SERVICES  RELATED TO THE PREVENTION AND TREATMENT OF
   30  SICKLE CELL DISEASE, TRAINING OF HEALTH PROFESSIONALS AND THE  IDENTIFI-
   31  CATION  AND  ESTABLISHMENT OF OTHER EFFORTS RELATED TO THE EXPANSION AND
   32  COORDINATION OF EDUCATION, TREATMENT, AND CONTINUITY  OF  CARE  PROGRAMS
   33  FOR SUCH INDIVIDUALS.
   34    S 5. This act shall take effect immediately.
feedback